← Back to Knowledge Base

Primary topic: ELOVL2 gene cholesterol and blood-fat handling

ELOVL2 Gene and Metabolism: What It Can Mean in a Pathway Report

ELOVL2 is tracked because it connects to lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling. The current evidence index links this gene to Lipids with 1 SNP and 1 curated claim.

What is the ELOVL2 gene?

Very-long-chain fatty-acid elongase involved in EPA, DPA, DHA, and long-chain PUFA handling.

How ELOVL2 affects metabolism

When ELOVL2-related function is shifted, the practical effect is interpreted through lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling. This does not mean the pathway is active or impaired right now; it means the gene can help prioritize what to check next.

What happens when ELOVL2 is altered

Altered ELOVL2 signal should be treated as a DNA-based tendency, not a diagnosis. 1 claim currently passes the report-use gate. The useful question is whether symptoms, labs, and lifestyle context line up with the pathway signal.

Curated SNP evidence for ELOVL2

These SNPs come from the approved study-level evidence model. Each claim is scored from curated study rows, then gated before it can influence pathway scoring.

Evidence-backed report connection

ELOVL2 currently has 1 curated SNPs, 1 claim-level scores, and 1 claims eligible for pathway scoring.

Open the sample report
rs953413ELOVL2 rs9534131 claims · 2 study rows

biomarker tendency · A

omega-3 long-chain PUFA response tendency

Moderate

rs953413 A in ELOVL2 is associated with altered EPA/DHA proportions and a stronger EPA or omega-3 index increase after fish-oil supplementation.

ELOVL2 rs953413 A is staged as a fish-oil response and long-chain omega-3 PUFA biomarker allele.

Likely effectHigher biomarker tendency
Signal sizeSmall signal
Evidence supportStrong support
Report useIncluded in pathway scoring
Show study evidence

Common symptoms people report

  • unexpected cholesterol or triglyceride results
  • family context around lipid markers
  • unclear ApoB, LDL-C, HDL-C, or triglyceride patterns

Biomarkers to validate

ApoB

Shows the number of atherogenic particles more directly than total cholesterol.

LDL-C, HDL-C, and triglycerides

Gives the basic lipid pattern that DNA can help contextualize.

Lp(a) or liver enzymes when relevant

Adds context for inherited lipid risk or liver lipid handling.

Where DNA analysis helps

DNA helps decide whether ELOVL2 deserves attention inside the broader Lipids pathway. It is most useful when combined with biomarkers instead of used as a standalone answer.

Example interpretation

ELOVL2 may add context to lipoprotein transport, triglyceride-rich particles, LDL clearance, or liver lipid handling, especially when its SNP evidence lines up with other genes in the same pathway.

Suggested validation: ApoB.

What to do next

  • Review the Lipids pathway result before interpreting ELOVL2 on its own.
  • Use relevant biomarkers to confirm whether this DNA tendency is visible in current biology.
  • Treat supplement or nutrition decisions as follow-up steps only after the pattern fits symptoms or labs.

Upload your DNA file and receive a structured metabolic pathway analysis with prioritized insights and suggested validation markers.

Get My DNA Report

Related pages